Amneal has closed its purchase of Kashiv BioSciences, and the shares it handed the sellers count toward the ownership of the founding group that some of those sellers belong to

$375m in cash, 28,942,098 shares, and up to $350m more if six drug candidates get through the regulator.

That is what Amneal Pharmaceuticals paid on Monday for all of Kashiv BioSciences, under a purchase agreement signed on 21 April and closed on 10 August. The buyer of record is Amneal Pharmaceuticals LLC, a wholly owned subsidiary. It took 100 percent of the membership interests.

The cash figure is not final. It is subject to adjustment for cash, indebtedness, transaction expenses, the funding of Kashiv's operations between signing and closing up to a specified cap, and working capital measured against a target.

The sellers are not strangers

The filing says so itself, in a single sentence and without elaboration: certain of the Sellers are affiliates of the Amneal Group, as that term is defined in the proxy statement the company filed on 25 March.

What makes the point concrete is the second agreement signed on Monday. Amneal entered a First Amendment to its Third Amended and Restated Stockholders Agreement with Vikram Patel, acting as the Amneal Group Representative. The amendment adjusts the definitions of Amneal Group and Amneal Group Member, and it clarifies that the stock issued in this transaction to members of that group counts toward the number of shares the group owns for all purposes of the Stockholders Agreement.

So the shares do double duty. They pay for a business, and they register on the ownership ledger that governs the group's rights.

Ten shares, and why they are missing

The introductory note says Amneal was required to issue 28,942,108 shares. The item covering the issuance says it issued 28,942,098.

The gap is ten shares and the document explains it. The lower figure is described as adjusted downward for fractional shares under the purchase agreement, which is the ordinary mechanical rounding that happens when a share number is derived from a formula rather than agreed as a round lot. The stock went out under the private placement exemption in Section 4(a)(2), with the sellers representing that they are accredited investors buying for investment rather than for resale. Amneal has agreed to file a registration statement on Form S-3 so those shares can later be sold publicly.

The bill keeps arriving for twelve years

Beyond the closing consideration sit two tails.

The first is milestone money. Up to $350,000,000 more becomes payable if certain United States regulatory milestones are achieved for as many as six designated Kashiv product candidates. The filing does not name them.

The second runs longer. For twelve years after closing, the sellers are eligible for royalty payments equal to 25 percent of the amount by which annual aggregate gross profits on certain products exceed specified hurdles. That is a share of the upside rather than a fixed sum, and it is measured year by year.

How the cash half was funded

On the same day, Amneal LLC and several subsidiary guarantors signed Amendment No. 4 to their term loan credit agreement, with JPMorgan Chase as administrative agent. Under it, Bank of America made an incremental term loan of $350,000,000, structured as an increase to the existing Amendment No. 3 term loans. The proceeds went toward the purchase price.

The underlying credit agreement dates from November 2023. Both new agreements are attached to Monday's filing as exhibits.